Company intelligence / Profile preview

Zenova BioPharma

Waltham, Massachusetts, USAzenasbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for autoimmune diseases. Its lead candidate, obexelimab—a bifunctional monoclonal antibody targeting CD19 and FcγRIIb—is in global Phase III trials for IgG4-related disease and Phase II trials for multiple sclerosis and systemic lupus erythematosus. The company has also entered into strategic licensing agreements with major pharmaceutical partners such as Bristol Myers Squibb to expand the reach of its therapies in Asia-Pacific markets[5][7].

Therapeutic areas: ImmunologyNeurologyHematology
Modalities: Monoclonal antibodies (mAbs)Immunology-based biologics
Industry: Biotech

Partnerships

Bristol Myers Squibb—strategic license and collaboration agreement covering South Korea, Taiwan, Singapore, Hong Kong, Australia[5].

Beyond the preview

Go deeper on Zenova BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zenova BioPharma.